Page last updated: 2024-08-16

temozolomide and quinuclidines

temozolomide has been researched along with quinuclidines in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A	1
Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S	1
Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T	1
Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV	1

Trials

2 trial(s) available for temozolomide and quinuclidines

Article	Year
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:5 Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting	2011
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:10 Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quality of Life; Quinuclidines; Surveys and Questionnaires; Temozolomide	2016

Article

Year

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:5

Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting

2011

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:10

Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quality of Life; Quinuclidines; Surveys and Questionnaires; Temozolomide

2016

Other Studies

2 other study(ies) available for temozolomide and quinuclidines

Article	Year
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. Neurologia medico-chirurgica, 2016, Nov-15, Volume: 56, Issue:11 Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting	2016
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. International journal of oncology, 2021, Volume: 58, Issue:3 Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mutation; Panobinostat; Quinuclidines; Temozolomide; Tumor Suppressor Protein p53	2021

Article

Year

Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.

Neurologia medico-chirurgica, 2016, Nov-15, Volume: 56, Issue:11

Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting

2016

APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.

International journal of oncology, 2021, Volume: 58, Issue:3

Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mutation; Panobinostat; Quinuclidines; Temozolomide; Tumor Suppressor Protein p53

2021